May 7, 2020 | News
SUGAR LAND, TX – (May 7, 2020) Healix Infusion Therapy is pleased to announce that its collaborative research study regarding Immune Globulin Subcutaneous 16.5% (Cutaquig®) is now accessible in the AAAAI Annual Meeting Virtual Poster Hall. The study by authors Richard...
May 6, 2020 | News
The team at Healix would like to recognize and thank nurses across the nation for their dedication to the nursing profession and the time they sacrifice away from their loved ones to care for those in need. Nurses play a critical role not only in our healthcare system...
Apr 14, 2020 | News
SUGAR LAND, TX – (March 20, 2020) Healix Infusion Therapy, LLC, announced today the publication of a collaborative study in the leading scientific journal, Open Forum Infectious Diseases. This real-world multicenter study demonstrated successful prevention of...
Apr 13, 2020 | News
The team at Healix would like to thank all the healthcare heroes who are on the front lines treating patients during this unprecedented time with the COVID-19 crisis. We know you are faced with new challenges every day, and we are sincerely grateful, now more than...
Oct 7, 2019 | News
Healix is proud to celebrate over 30 years of infusion excellence. Since its founding in 1989, the company has revolutionized infusion therapy nationwide within the physician office site of care, maintaining a steadfast focus on providing patient and physician peace...
May 29, 2019 | News
Healix Infusion Therapy Selected as Limited Distribution Network Partner for Cutaquig®, Octapharma’s new 16.5% Subcutaneous Immune Globulin. SUGAR LAND, TX ( May 29, 2019) – Healix Infusion Therapy is pleased to announce that it has been selected as a limited...
Recent Comments